[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Second Hospital of Anhui Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":365},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,42,60,85,112,136,171,193,219,245,262,290,320,342],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643496","the-effect-of-esketamine-on-cough-reflex-during-tracheal-extubation-in-patients-undergoing-non-inflatable-transoral-endoscopic-thyroid-surgery-100643496",false,"NCT07641673","The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Non-inflatable Transoral Endoscopic Thyroid Surgery","The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Non-inflatable Transoral Endoscopic Thyroid Surgery: A Randomized Controlled Study.","Inclusion Criteria:\n\n* Patients scheduled for endotracheal intubation-free thyroid surgery under oral endoscopy\n* ASA class I-II\n* Voluntarily participate in the study and sign the informed consent form\n\nExclusion Criteria:\n\n* Body Mass Index \\> 30 kg\u002Fm²\n* Patients with unstable ischemic cardiomyopathy, pulmonary hypertension, poorly controlled or untreated hypertension (arterial hypertension, resting systolic\u002Fdiastolic blood pressure \\>180\u002F100 mmHg)\n* Hepatic or renal dysfunction\n* History of oral, maxillofacial, neck, or airway surgery, or pathological structural alterations\n* Respiratory diseases (COPD, asthma, inflammation, chronic cough)\n* Patients with elevated intracranial pressure\n* Patients undergoing repeat surgery\n* History of allergy to the investigational drug used in the study\n* Patients with psychiatric disorders or alcohol abuse (daily ethanol intake ≥40 g, or having experienced alcohol withdrawal within the past 6 months, or unable to control alcohol consumption)","ALL","18 Years","65 Years",{"count":20,"type":21},186,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study intends to implement esketamine-assisted anesthesia in patients undergoing non-inflatable transoral endoscopic thyroidectomy through a prospective randomized controlled trial, in order to observe the effect of esketamine on coughing during extubation in thyroidectomy patients.",[27,28],"Thyroidectomy","Coughing Reflex","NOT_YET_RECRUITING","2026-06-07",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":21},"2026-06",{"date":37,"type":21},"2027-09",{"name":39,"class":40},"The Second Hospital of Anhui Medical University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":59,"locationsCount":41},"100638116","the-effect-of-esketamine-on-cough-reflex-during-tracheal-extubation-in-patients-undergoing-open-thyroid-surgery-100638116","NCT07625826","The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Open Thyroid Surgery","The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Open Thyroid Surgery: A Randomized Controlled Study","Inclusion Criteria:\n\n* Patients scheduled for elective open thyroid surgery\n* ASA class I-II\n* Voluntarily participate in the study and sign the informed consent form\n\nExclusion Criteria:\n\n* Body Mass Index \\> 30 kg\u002Fm²\n* Patients with unstable ischemic cardiomyopathy, pulmonary hypertension, poorly controlled or untreated hypertension (arterial hypertension, resting systolic\u002Fdiastolic blood pressure \\>180\u002F100 mmHg)\n* Hepatic or renal dysfunction\n* History of oral, maxillofacial, neck, or airway surgery, or pathological structural alterations\n* Respiratory diseases (COPD, asthma, inflammation, chronic cough)\n* Patients with elevated intracranial pressure\n* Patients undergoing repeat surgery\n* History of allergy to the investigational drug used in the study\n* Patients with psychiatric disorders or alcohol abuse (daily ethanol intake ≥40 g, or having experienced alcohol withdrawal within the past 6 months, or unable to control alcohol consumption)",{"count":50,"type":21},136,[24],"This study intends to conduct a prospective randomized controlled trial to implement esketamine-assisted anesthesia in patients undergoing open thyroidectomy, in order to observe the effect of esketamine on coughing during extubation in thyroidectomy patients.",[27,28],"2026-06-03",{"date":56,"type":33},"2026-06-04",{"date":35,"type":21},{"date":37,"type":21},{"name":39,"class":40},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100621631","effects-of-aromatherapy-on-sleep-quality-in-hospitalized-elderly-female-patients-with-insomnia-100621631","NCT07373132","Effects of Aromatherapy on Sleep Quality in Hospitalized Elderly Female Patients With Insomnia","Effects of Aromatherapy on Sleep Quality in Hospitalized Elderly Female Patients With Insomnia: Protocol for A Randomized, Double-Blind, Placebo-Controlled Parallel Trial","Inclusion Criteria:\n\n* Female, aged ≥60 years.\n* Hospitalized in the Second Affiliated Hospital of Anhui Medical University.\n* Athens Insomnia Scale (AIS) \\>6.\n* Ability to communicate and understand instructions.\n* Non-allergic to essential oils.\n* Fully informed and voluntarily consent to participate.\n\nExclusion Criteria:\n\n* Cognitive impairment-.\n* History of hypersensitivity to aromatherapy oils.\n* Use of sedative-hypnotic medications within past 2 weeks.\n* Sleep disorders secondary to organic or psychiatric diseases.\n* Unable to comply with study procedures.",true,"FEMALE","60 Years","100 Years",{"count":72,"type":21},64,[24],"To evaluate the efficacy and safety of standardized aromatherapy compared with placebo in improving sleep quality among hospitalized elderly female patients with insomnia.",[76],"Insomnia","2026-05-25",{"date":79,"type":33},"2026-05-27",{"date":81,"type":21},"2026-05-01",{"date":83,"type":21},"2027-01-31",{"name":39,"class":40},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":41},"100631391","transcranial-direct-current-stimulation-for-depression-100631391","NCT07500064","Transcranial Direct Current Stimulation for Depression","A Comparative Study of the Clinical Efficacy of Transcranial Direct Current Stimulation Targeting the DLPFC Versus DMPFC in the Treatment of Depression","Inclusion Criteria:\n\n* The diagnosis meets the criteria for depression outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n* Age between 18 and 65 years.\n* Education level exceeding 5 years, with no significant hearing or visual impairments.\n* Voluntary signing of informed consent and ability to cooperate with general demographic data collection and neuropsychological scale testing.\n\nExclusion Criteria:\n\n* Age under 18 or over 65.\n* Patients with neurological disorders such as epilepsy or severe physical illnesses.\n* Patients with comorbid neuropsychiatric disorders, such as schizophrenia or obsessive-compulsive disorder.\n* Patients unable to undergo tDCS treatment for any reason, including presence of ferromagnetic metal in the head or implanted medical devices in the head\u002Fneck region.\n* Pregnant or lactating women.",{"count":93,"type":21},50,[24],"Background:\n\nDepression is a common mental disorder characterized by persistent low mood and anhedonia. Pharmacological and psychotherapeutic treatments demonstrate only moderate efficacy. Non-invasive brain stimulation techniques offer novel therapeutic approaches. Among these, transcranial direct current stimulation (tDCS) holds advantages due to its simplicity, low cost, and minimal side effects, exhibiting good efficacy and tolerability in depression treatment. The dorsolateral prefrontal cortex (DLPFC), a core region of the cognitive control network, serves as a traditional target for non-invasive brain stimulation in depression and plays a crucial role in positive affect (PA) processing. Conversely, the dorsomedial prefrontal cortex (DMPFC), a central region of the default mode network, participates in negative self-referential processing and negative affect (NA) regulation, demonstrating potential as a novel therapeutic target.\n\nObjective:\n\nGiven the distinct roles of DLPFC and DMPFC in separate affective regulation networks, this study aims to investigate the differential effects of different tDCS targets on emotional regulation in patients with depression.\n\nDesign:\n\nThis study employed a randomized, double-blind, controlled design. Participants diagnosed with depression will be randomly assigned to receive either effective tDCS targeting the left DLPFC or effective tDCS targeting the DMPFC. Primary outcome measures focus on changes in clinical symptom assessments.",[97],"Depression",[99,100,101,102],"depression","transcranial direct current stimulation","dorsolateral prefrontal cortex","dorsomedial prefrontal cortex","RECRUITING","2026-05-14",{"date":106,"type":33},"2026-05-19",{"date":108,"type":33},"2026-03-30",{"date":110,"type":21},"2027-12-31",{"name":39,"class":40},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":41},"100635597","tis-for-nssi-in-adolescent-depression-100635597","NCT07554755","TIS for NSSI in Adolescent Depression","Efficacy and Safety of Temporal Interference Stimulation on Non-suicidal Self-injury Behaviors in Adolescents With Depression","Inclusion Criteria:\n\n1. Meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition) diagnostic criteria for major depressive disorder.\n2. Patients aged 12-22 years with at least one guardian to monitor them for 3 months\n3. HAMD-17 Total score ≥18\n4. Patients who had two or more non-suicidal self-injury behaviors meeting the 5.DSM-5 diagnostic criteria in the 2 weeks before admission (NSSI behavior of more than 5 days in the past year)\n\n6.Obtain informed consent from patients and guardians\n\n\\-\n\nExclusion Criteria:\n\n1. Substance abusers such as psychoactive drugs or alcohol.\n2. Severe physical disability and unable to complete follow-up.\n3. Comorbid other major mental illnesses that meet the DSM-5 criteria, such as bipolar disorder, schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc.\n4. Suffering from any severe physical disease, neurological disease, traumatic brain injury, etc, that affects the structure or function of the brain in the lifetime.\n\n   Unable to read, understand and complete the assessment or to cooperate with the investigators.\n5. Any implants covering a pacemaker, metallic or magnetic objects in the body, or other conditions not suitable for TIS.\n6. Those who have received systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavioral therapy) or TMS within 3 months before baseline.\n7. Other examination abnormalities considered to be inappropriate by investigators.\n\n   \\-","12 Years","22 Years",{"count":122,"type":21},60,[24],"Temporal Interference Stimulation (TIS) has been successfully used to help patients with depression. However, its role in alleviating self injuries remained uncertain. This trial will compare the effectiveness of TIS to a placebo control on non-suicidal self injury (NSSI) in patients with major depressive disorder(MDD).",[126,127,128],"Temporal Interference Stimulation","Non Suicidal Self Injury","Major Depressive Disorder","2026-04-23",{"date":131,"type":33},"2026-04-28",{"date":133,"type":21},"2026-04-30",{"date":83,"type":21},{"name":39,"class":40},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":157,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},"100607166","intra-arterial-thrombolysis-for-acute-ischemic-stroke-with-medium-vessel-occlusion-100607166","NCT07185022","Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion","a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)","RESCUE MeVO","Inclusion Criteria:\n\n* Age \\> 18 years\n* Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA)\n* The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction)\n* Intra-arterial thrombolysis was administered within the following time windows:\n\n  1. Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA;\n  2. Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume \\\u003C30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Pre-stroke mRS ≥ 2\n* Secondary MeVO or severe stenosis caused by endovascular therapy\n* Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders\n* Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory\n* Platelet count \\\u003C100 × 10⁹\u002FL, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) \\>3.0\n* Persistent and uncontrolled hypertension, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg\n* History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage\n* Presence of arteriovenous malformations or brain tumors with mass effect\n* Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months\n* Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL)\n* Patients with known allergy to thrombolytic agents or their excipients\n* Patients with known allergy to iodinated contrast agents or other established contraindications\n* Pregnant or current breastfeeding\n* Presence of severe systemic comorbidities with a life expectancy of less than 3 months\n* Deemed unsuitable for participation by the investigator for any reason",{"count":145,"type":21},282,[24],"Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.",[149,150,151,152,153,154,155,156],"Stroke","Cerebrovascular Disorders","Brain Diseases","Nervous System Diseases","Vascular Diseases","Ischemic Stroke","Infarction","Medium Vessel Occlusion",[158,159,149,160,161],"Ischemic stroke","Medium vessel occlusion","Intra-arterial thrombolysis","Severe stenosis","2026-04-13",{"date":164,"type":33},"2026-04-16",{"date":166,"type":33},"2026-01-06",{"date":168,"type":21},"2030-05-01",{"name":39,"class":40},6,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":67,"sex":16,"minAge":119,"maxAge":18,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100633983","investigating-functional-changes-in-the-frontotemporal-cortex-of-patients-with-major-depressive-disorder-following-electroconvulsive-therapy-or-magnetic-seizure-therapy-using-functional-near-infrared-spectroscopy-fnirs-100633983","NCT07533773","Investigating Functional Changes in the Frontotemporal Cortex of Patients With Major Depressive Disorder Following Electroconvulsive Therapy or Magnetic Seizure Therapy Using Functional Near-infrared Spectroscopy (fNIRS)","Investigating Functional Changes in the Frontotemporal Cortex of Patients With Major Depressive Disorder Following Electroconvulsive Therapy or Magnetic Seizure Therapy Using Functional Near-infrared Spectroscopy","Inclusion Criteria:\n\n* A depressive episode diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by two psychiatrists;\n* Meets the treatment criteria for ECT or MST;\n* At least 5 years of education, with no significant hearing or visual impairments;\n* Voluntary participation in this study, with a signed written informed consent form, and willingness to cooperate with the collection of general demographic information, neuropsychological testing, and fNIRS resting-state and task-based data acquisition.\n\nExclusion Criteria:\n\n* Co-occurring mental disorders (such as substance use disorders or schizoaffective disorder);\n* Severe physical illness;\n* History of neurological disorders (such as traumatic brain injury or dementia);\n* Low educational attainment;\n* Receipt of ECT or MST treatment within the past six months.",{"count":122,"type":21},[24],"Against the clinical backdrop of the growing global burden of neuropsychiatric disorders, the rapid rise in depression prevalence, and the frequent association of these conditions with cognitive impairment, this study highlights the limitations of current cognitive assessment tools-such as their time-consuming nature and lack of specificity-and underscores the urgent need to develop simple and efficient assessment methods. In terms of treatment, modified electroconvulsive therapy (ECT) and magnetic seizure therapy (MST) are rapidly acting neuromodulation therapies; however, their effects on cognitive function and underlying brain mechanisms remain controversial, and there is a lack of direct comparative studies. Functional near-infrared spectroscopy (fNIRS) technology can non-invasively monitor changes in cerebral hemodynamics, providing a powerful tool for assessing brain function before and after treatment. Therefore, this study aims to combine resting-state and task-based fNIRS with multidimensional cognitive and emotional assessments to systematically compare the effects of ECT and MST on frontal-temporal cerebral hemodynamics. We seek to clarify the differences in brain function regulation between the two treatment modalities and their association with improvements in cognition and mood, with the goal of providing scientific evidence to elucidate the brain mechanisms underlying neurostimulation therapies and optimize individualized treatment plans.",[182],"Major Depressive Disorder (MDD)",[128,184,185,186],"Electroconvulsive Therapy","Magnetic Seizure Therapy","Functional Near-Infrared Spectroscopy","2026-04-09",{"date":164,"type":33},{"date":133,"type":21},{"date":191,"type":21},"2029-04-30",{"name":39,"class":40},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":200,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":205,"conditions":206,"keywords":209,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":41},"100633722","early-phase-1-ucar-t-cell-therapy-targeting-cd19bcma-in-relapsedrefractory-autoimmune-hemolytic-anemia-100633722","NCT07530380","UCAR T-cell Therapy Targeting CD19\u002FBCMA in Relapsed\u002FRefractory Autoimmune Hemolytic Anemia","A Clinical Study of CD19\u002FBCMA-Targeted Universal Allogeneic CAR-T Cell Therapy in Relapsed\u002FRefractory Autoimmune Hemolytic Anima: Evaluating Safety and Preliminary Efficacy","Inclusion Criteria:\n\n* 1\\. Age ≥ 10 years, regardless of sex;\n* 2\\. Flow cytometry-confirmed CD19 or BCMA positivity on B cells in peripheral blood or bone marrow;\n* 3\\. Patients diagnosed with AIHA, including warm antibody type, cold agglutinin disease, mixed type, and other types of AIHA, with diagnostic criteria referring to the \"Chinese Adult Autoimmune Hemolytic Anemia Diagnosis and Treatment Guidelines (2023 Edition)\";\n* 4\\. The definition of recurrent\u002Frefractory AIHA that has received at least 3 failed lines of treatment is symptomatic anemia (hemoglobin\\\u003C100g\u002F L) that persists after a routine treatment cycle of at least 6 months and is still ineffective or reappears after disease remission. The definition of conventional treatment: treatment with glucocorticoids and\u002For rituximab, as well as any 1-2 or more of the following immunomodulatory drugs: cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine A, azathioprine, danazol, bendamustine, fludarabine, bortezomib, and biologics including daratumumab, BTK inhibitors, Syk inhibitors, and complement inhibitors;\n* 5\\. Functional requirements for major organs are as follows:\n\n  1. The bone marrow function needs to meet: a Neutrophil count ≥ 1.0\n\n     × 10 \\^ 9\u002FL; b. Platelets ≥ 30 × 10 \\^ 9\u002FL.\n  2. Liver function: ALT ≤ 3 × UL; AST ≤ 3×ULN# Total bilirubin ≤ 2.0 × ULN (excluding Gilbert syndrome, total bilirubin ≤ 3.0 × ULN).\n  3. Renal function: creatinine clearance rate (CrCl) ≥ 30 ml\u002Fmin (Cockcroft\u002FGault formula, excluding acute CrCl decline caused by the disease itself).\n* 6\\. ECOG ≤ 2;\n* 7\\. Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating;\n* 8\\. Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* 1\\. Subjects with a history of severe drug allergies or allergic tendencies;\n* 2\\. Presence or suspicion of uncontrolled or treatment-required fungal, bacterial, viral, or other infections;\n* 3\\. History of recurrent infections (e.g., ≥3 episodes of active infection requiring medical intervention within 6 months prior to enrollment);\n* 4\\. History of cytomegalovirus (CMV), Epstein-Barr virus (EBV), or fungal infections within 3 months prior to screening, or history of recurrent CMV, EBV, or fungal infections;\n* 5\\. Receipt of any vaccination within 12 weeks prior to enrollment, or participation in a vaccine clinical trial within 12 weeks prior to enrollment;\n* 6\\. Subjects with insufficient cardiac function;\n* 7\\. Moderate to severe congestive heart failure (New York Heart Association \\[NYHA\\] Class III-IV);\n* 8\\. Subjects with congenital immunoglobulin deficiencies;\n* 9\\. History of malignancy within the past 5 years (except for non-melanoma skin cancer, completely resected Stage I tumor with low risk of recurrence, treated clinically localized prostate cancer, biopsy-proven cervical carcinoma in situ or squamous intraepithelial lesion on smear, and stable papillary or follicular thyroid cancer);\n* 10\\. Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA \\>ULN; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing;\n* 11\\. History of organ transplantation, including but not limited to bone marrow or hematopoietic stem cell transplantation;\n* 12\\. Severe, progressive, uncontrolled disease of the cardiovascular, cerebrovascular, hepatic, renal, pulmonary, gastrointestinal, hematologic, endocrine, or nervous system;\n* 13.Psychiatric disorder or severe cognitive impairment;\n* 14\\. Pregnant women or women planning to conceive\n* 15\\. Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study","10 Years",{"count":202,"type":21},15,[204],"EARLY_PHASE1","This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19\u002FBCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy",[207,208],"AIHA - Warm Autoimmune Hemolytic Anemia","UCART",[210,208],"AIHA","2026-04-08",{"date":213,"type":33},"2026-04-15",{"date":215,"type":21},"2026-04",{"date":217,"type":21},"2030-12-31",{"name":39,"class":40},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":67,"sex":16,"minAge":119,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":41},"100629359","multimodal-clinical-study-of-electroconvulsive-therapy-and-magnetic-seizure-therapy-100629359","NCT07473648","Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy","Patients Inclusion Criteria:\n\nAged 12-80 years; Diagnosis confirmed by two psychiatrists per DSM-5; Stable medication regimen pre-enrollment; Indicated for neuromodulation OR with visual field defects.\n\nPatients Exclusion Criteria:\n\nMajor systemic diseases; Prior neuromodulation within 3 months; Pregnancy or potential pregnancy; Metal implants or claustrophobia.\n\nHealthy Control Inclusion Criteria:\n\nAged 12-80 years; No history of neuropsychiatric disorders; No significant systemic diseases; Normal or corrected vision.\n\nHealthy Control Exclusion Criteria:\n\nMetal implants or claustrophobia; Ocular diseases or surgery history.","80 Years",{"count":227,"type":21},200,[24],"To compare the efficacy and tolerability of Electroconvulsive Therapy (ECT) and Magnetic Seizure Therapy (MST) in patients with major depressive disorder (MDD).",[184,128,185],[232,233,234,235,236],"Electroconvulsive Therapy (ECT)","Magnetic Seizure Therapy(MST)","Major Depressive Disorder(MDD)","Electroencephalography(EEG)","Resting-state Functional MRI (fMRI)","2026-03-10",{"date":239,"type":33},"2026-03-16",{"date":241,"type":33},"2025-09-01",{"date":243,"type":21},"2028-01",{"name":39,"class":40},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":67,"sex":16,"minAge":119,"maxAge":69,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":260,"locationsCount":261},"100607656","intervention-effect-of-temporal-interference-stimulation-tis-on-depressive-disorder-100607656","NCT07191392","Intervention Effect of Temporal Interference Stimulation (TIS) on Depressive Disorder","Inclusion Criteria:\n\n* the patients were diagnosed by more than 2 psychiatrists and met the diagnostic criteria of DSM-5 for depression, and HAMD\\>17, BSS\\>6, PHQ-15\\>5.\n* the age ranged from 18 to 65 years old, and the length of education was more than 5 years.\n* the visual acuity or corrected visual acuity is normal, right-handed, can cooperate with the completion of various experimental tests.\n\nExclusion Criteria:\n\n* accompanied by severe somatic diseases, such as severe heart, liver, renal insufficiency and so on.\n* accompanied by other neurological diseases, such as stroke, epilepsy and so on. pregnant and lactating women.\n* accompanied by other mental disorders, such as drug abuse, schizophrenia, schizophrenic affective",{"count":122,"type":21},[24],"To investigate the effect of Temporal Interference Stimulation (TIS) on associative memory (AM) in patients with depressive disorder",[255,126],"Depressive Disorder","2026-03-09",{"date":237,"type":33},{"date":241,"type":33},{"date":35,"type":21},{"name":39,"class":40},2,{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},"100588878","stellate-ganglion-morphine-infiltration-on-myocardial-ischemia-reperfusion-injury-100588878","NCT06947135","Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury","The Effect of Targeted Stellate Ganglion Morphine Infiltration on Reperfusion Injury in STEMI Patients After Primary PCI: A Randomized Controlled Trial","tSGM-AMI","Inclusion Criteria:\n\n1. Aged ≥18 years, Male or Female.\n2. Acute ST-segment elevation myocardial infarction (STEMI) patients planned for percutaneous coronary intervention (PCI). Acute STEMI is defined as: electrocardiogram shows ST-segment elevation ≥0.2 mV in two or more adjacent leads, or new left bundle branch block (LBBW).\n3. Within 24 hours of the onset of infarct-related chest pain.\n4. Obtaining informed consent from the patient and their family.\n\nExclusion Criteria:\n\n1. Patients with severe complications of myocardial infarction, such as uncontrollable acute left heart failure and pulmonary edema, severe cardiogenic shock after cardiopulmonary resuscitation, severe mechanical complications including ventricular septal defect, papillary muscle rupture, and rupture of the left ventricular free wall;\n2. Patients with old myocardial infarction, or cardiomyopathy, or malignant arrhythmias controlled by antiarrhythmic drugs;\n3. Patients with coagulation disorders due to systemic diseases and those who are currently using anticoagulants and are not suitable for injection;\n4. Patients allergic to opioids or with a history of opioid addiction and those participating in other clinical studies;\n5. Pregnant or breastfeeding women;\n6. Patients with severe organ dysfunction or failure, such as liver failure, renal failure, and respiratory failure;\n7. Patients with severe infections;\n8. Patients with severe mental illness that cannot cooperate and those taking antipsychotic drugs;\n9. Other patients considered unsuitable for this study by the researchers.",{"count":271,"type":21},166,[24],"The goal of this clinical trial is to investigate whether morphine modulates the functions of the stellate ganglion to reduce myocardial ischemia\u002Freperfusion injury in AMI patients. It will also assess the safety of injecting morphine around the stellate ganglion via ultrasound guidance. The main questions it aims to answer are:\n\n1. Does morphine regulate stellate ganglion function to reduce myocardial ischemia\u002Freperfusion injury in AMI patients?\n2. What medical problems do participants experience when receiving injected morphine around the stellate ganglion? Researchers will compare morphine to a placebo saline (as a control group) to determine whether stellate ganglion infiltration with morphine effectively treats patients with AMI following primary PCI.\n\nParticipants will:\n\n* Receive a single injection of morphine or saline around the stellate ganglion.\n* Evaluate the percentage of infarct size 7 days after surgery, or at discharge if the duration is shorter than 7 days.\n* Record their symptoms and any major adverse cardiovascular and cerebrovascular events within 30 days post-surgery.",[275],"Acute Myocardial Infarction",[275,277,278,279,280],"Stellate Ganglion","Percutaneous Coronary Intervention","Ischemia\u002Freperfusion injury","Morphine","2025-12-09",{"date":283,"type":33},"2025-12-17",{"date":285,"type":33},"2025-05-29",{"date":287,"type":21},"2026-06-30",{"name":39,"class":40},3,{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":225,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":306,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":319},"100599727","statins-for-treatment-of-primary-intracerebral-hemorrhage-100599727","NCT07088250","Statins for Treatment of Primary Intracerebral Hemorrhage","Statins for Treatment Of Primary IntraCerebral Hemorrhage (STOP ICH)","STOP ICH","Inclusion Criteria:\n\n* Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT);\n* Age 18-80 years;\n* Hematoma located in the supratentorial region;\n* Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours;\n* Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well;\n* Glasgow Coma Scale (GCS) score ≥9;\n* Baseline hematoma volume of 5-35 mL;\n* Signed informed consent obtained.\n\nExclusion Criteria:\n\n* ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH;\n* Patients who have undergone or are scheduled for immediate surgical intervention;\n* Pregnancy or lactation;\n* Use of oral anticoagulants within 1 month prior to symptom onset;\n* Pre-stroke mRS \\>1;\n* Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis;\n* Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care.",{"count":299,"type":21},264,[24],"The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.",[150,303,304,305],"Intracranial Hemorrhages","Intracranial Hemorrhage","Intracerebral Haemorrhage",[307,308,309,310],"Intracerebral hemorrhage","Treatment","Atorvastatin","Outcome","2025-07-20",{"date":313,"type":33},"2025-07-28",{"date":315,"type":33},"2023-05-06",{"date":317,"type":21},"2026-12-31",{"name":39,"class":40},22,{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":268,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":261},"100594763","stellate-ganglion-morphine-infiltration-on-myocardial-ir-injury-100594763","NCT07023679","Stellate Ganglion Morphine Infiltration on Myocardial I\u002FR Injury","The Effect of Targeted Stellate Ganglion Morphine Infiltration on Reperfusion Injury in STEMI Patients After Primary PCI: A Multi-Center Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged ≥18 years, Male or Female.\n* Acute ST-segment elevation myocardial infarction (STEMI) patients planned for percutaneous coronary intervention (PCI). Acute STEMI is defined as: electrocardiogram shows ST-segment elevation ≥0.2 mV in two or more adjacent leads, or new left bundle branch block (LBBW).\n* Within 24 hours of the onset of infarct-related chest pain.\n* Obtaining informed consent from the patient and their family.\n\nExclusion Criteria:\n\n* Patients with severe complications of myocardial infarction, such as uncontrollable acute left heart failure and pulmonary edema, severe cardiogenic shock after cardiopulmonary resuscitation, severe mechanical complications including ventricular septal defect, papillary muscle rupture, and rupture of the left ventricular free wall;\n* Patients with old myocardial infarction, or cardiomyopathy, or malignant arrhythmias controlled by antiarrhythmic drugs;\n* Patients with coagulation disorders due to systemic diseases and those who are currently using anticoagulants and are not suitable for injection;\n* Patients allergic to opioids or with a history of opioid addiction and those participating in other clinical studies;\n* Pregnant or breastfeeding women;\n* Patients with severe organ dysfunction or failure, such as liver failure, renal failure, and respiratory failure;\n* Patients with severe infections;\n* Patients with severe mental illness that cannot cooperate and those taking antipsychotic drugs;\n* Other patients considered unsuitable for this study by the researchers.",{"count":328,"type":21},2588,[24],"The goal of this clinical trial is to investigate whether morphine modulates the functions of the stellate ganglion to reduce myocardial ischemia\u002Freperfusion (I\u002FR) injury in AMI patients. It will also assess the safety of injecting morphine around the stellate ganglion via ultrasound guidance. The main questions it aims to answer are:\n\n1\\. Does morphine regulate stellate ganglion function to reduce myocardial I\u002FR injury in AMI patients and improve one year outcome in AMI patients? 3. What medical problems do participants experience when receiving injected morphine around the stellate ganglion? Researchers will compare morphine to a placebo saline (as a control group) to determine whether stellate ganglion infiltration with morphine effectively treats patients with AMI following primary PCI.\n\nParticipants will:\n\n* Receive a single injection of morphine or saline around the stellate ganglion.\n* Evaluate the myocardial injury during their duration of hospital stay.\n* Record their symptoms and any major adverse cardiovascular and cerebrovascular events within one year post-surgery.",[332],"Acute Myocardial Infarction (AMI)",[275,277,278,279,280],"2025-07-03",{"date":336,"type":33},"2025-07-04",{"date":338,"type":33},"2025-06-24",{"date":340,"type":21},"2029-06-20",{"name":39,"class":40},{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":355,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":41},"100589806","endovascular-treatment-beyond-24-hours-for-acute-ischemic-stroke-caused-by-anterior-circulation-large-vessel-stenosis-100589806","NCT06959199","Endovascular Treatment Beyond 24 Hours for Acute Ischemic Stroke Caused by Anterior Circulation Large Vessel Stenosis","EndoVascular Treatment Beyond 24 Hours for AcutE Ischemic Stroke Caused by Anterior Circulation LArge Vessel STEnosis: A Multicenter RandomizeD Controlled Trial(EVT-BELATED)","EVT-BELATED","Inclusion criteria:\n\n* Age \\> 18 years\n* Acute ischemic stroke with a time window of 24 to 120 hours from symptom onset or last known well, or progressive ischemic stroke with a time from symptom onset of 24 hours to 7 days (A ≥4-point increase in NIHSS attributable to the culprit vessel territory )\n* NIHSS score 5-25\n* Occlusion or ≥70% stenosis of the internal carotid artery or the M1\u002FM2 segment of the middle cerebral artery, confirmed by CTA, MRA, or DSA, and deemed to be the culprit vessel responsible for the clinical presentation of acute ischemic stroke\n* Meet one of the following imaging criteria:\n\n  1. MRI-based criteria: the infarct volume on DWI is less than one-third of the MCA territory, with evidence of DWI-FLAIR mismatch or MR perfusion showing a core infarct volume ≤30 ml, a mismatch ratio ≥1.8, and a mismatch volume ≥15 ml;\n  2. CTA-based criteria: good collateral circulation on the affected side defined ascollateral filling \\>50% of the MCA territory (Tan score ≥2) and an ASPECTS score ≥6);\n  3. CTP-based criteria: ischemic core volume ≤30 ml, mismatch ratio ≥ 1.8, and mismatch volume ≥ 15mL\n* Signed informed consent obtained\n\nExclusion criteria:\n\n* Pre-stroke mRS ≥ 2\n* Patients unable to undergo vascular imaging\n* Patients with known allergies to iodine contrast agents, anesthetics, or any contraindication to endovascular treatment\n* Prior endovascular therapy performed after the index stroke event during the current hospitalization\n* Intracranial hemorrhage identified on initial imaging\n* Platelet count \\\u003C50×10⁹\u002FL, or presence of a known hemorrhagic diathesis , coagulation factor deficiencies, or use of oral anticoagulation therapy with an International Normalized Ratio (INR) \\> 3.0\n* Refractory hypertension, defined as sustained systolic blood pressure \\>200 mmHg or diastolic blood pressure \\>120 mmHg despite optimal medical management\n* History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage\n* Significant mass effect with midline shift confirmed by CT or MRI\n* Suspected cardioembolic stroke or stroke due to non-atherosclerotic etiologies, such as:arterial dissection,Moyamoya disease, Infective endocarditis, or Immune-mediated vasculitis\n* Prior intracranial stent placement in the same culprit vessel\n* Major surgery performed within the past 30 days\n* Pregnant or current breastfeeding\n* Presence of severe systemic comorbidities with a life expectancy of less than 3 months\n* Deemed unsuitable for participation by the investigator for any reason",{"count":351,"type":21},432,[24],"Endovascular therapy (EVT) is currently recommended as the first-line treatment for patients with acute large vessel occlusion (LVO) in the anterior circulation within 24 hours of symptom onset. However, the therapeutic benefit of EVT beyond 24-hour window remains uncertain due to limited evidence. The EVT-BELATED trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the safety and efficacy of EVT in patients with acute ischemic stroke (AIS) caused by anterior circulation LVO presenting beyond 24 hours after symptom onset.",[149,150,151,152,153,154,155],[158,356,149],"Endovascular therapy","2025-05-08",{"date":359,"type":33},"2025-05-14",{"date":361,"type":33},"2025-03-24",{"date":363,"type":21},"2029-12-30",{"name":39,"class":40},""]